NFE2L2 and neoplasm: The lymphocyte invasion score was higher in tumors exposed to 2.0 mg/kg of brusatol, suggesting that Nrf2 inhibition stimulates lymphocyte migration and potentially activates anti-tumor immunity (Figure 8).